Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

• To describe anatomical changes in the retina and choroid following the administration of PF-04523655 [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]
• To determine the changes in visual acuity ETDRS chart after a single intravitreal injection of PF-04523655 [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]
• To evaluate the safety, efficacy and frequency of dosing following administration of PF-04523655 of approved VEGF-inhibitors in those study patients requiring rescue therapy [ Time Frame: Monthly ] [ Designated as safety issue: Yes ]
• To evaluate early response after a single intravitreal administration of PF-04523655 in patients who, in the opinion of the investigator, have the potential to show improvement in visual acuity from other treatment options (Stratum 2 patients) [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]

The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD

Dose escalation safety study

Inclusion Criteria:

• Patient is ≥ 50 years old and in general good health. Patients with medically controlled chronic disease such as HTN, AODM, and hyperlipidemia may be included.
• Patient is capable of giving consent.
• Patient is willing and able to comply with the visit schedule and study procedures including follow-up visits.
• Patient has documented CNV secondary to AMD with evidence of active disease characterized by blood vessel leakage or evidence of hemorrhage.
• Patient has clear ocular media and adequate pupil dilation to allow good quality imaging by fundus photography.
• Patient's intraocular pressure is ≤ 25 mmHg

Exclusion Criteria:

• Patient is of childbearing potential. Every female patient is considered of child-bearing potential unless she has had sterilization surgery or is post-menopausal and has not had a menstrual period for at least 12 months.
• Patient has CNV due to causes other than AMD, including ocular or periocular infections.
• Patient has lesions not easily imaged and quantified.
• Patient has underlying systemic disease such as cardiac, neurological, infectious disease, uncontrolled diabetes mellitis, or disease of the eye other than AMD. Patient may have medically controlled glaucoma.
• Patient is participating in any concurrent interventional study.